COSMOS Pharmaceutical Corporation (3349) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

3349 Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

COSMOS

Pharmaceutical Corporation

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

3349 Stock 12 Month Forecast

Average Price Target

¥10,250.00

▲(34.11% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for COSMOS Pharmaceutical Corporation in the last 3 months. The average price target is ¥10,250.00 with a high forecast of ¥11,000.00 and a low forecast of ¥9,500.00. The average price target represents a 34.11% change from the last price of ¥7,643.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6635":"¥6,635","8818":"¥8,818","11001":"¥11,001","7726.5":"¥7,726.5","9909.5":"¥9,909.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6635,7726.5,8818,9909.5,11001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8474.72,8668.972307692307,8863.224615384615,9057.476923076923,9251.72923076923,9445.981538461538,9640.233846153846,9834.486153846154,10028.738461538462,10222.99076923077,10417.243076923078,10611.495384615384,10805.747692307692,{"y":11000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8474.72,8611.279999999999,8747.84,8884.4,9020.96,9157.52,9294.08,9430.64,9567.2,9703.76,9840.32,9976.880000000001,10113.44,{"y":10250,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8474.72,8553.587692307692,8632.455384615385,8711.323076923076,8790.190769230769,8869.058461538461,8947.926153846154,9026.793846153845,9105.661538461538,9184.52923076923,9263.396923076923,9342.264615384614,9421.132307692307,{"y":9500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7000.76,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7248.36,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7028.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7374.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6636,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6978.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7428.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9136.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8921.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9119.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9495.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8770.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8474.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥11,000

Average Price Target¥10,250

Lowest Price Target¥9,500

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sho Kawano

Goldman Sachs

¥9,000→¥9,500

Buy

24.30%

Upside

Upgraded

12/14/25

Upgraded to Buy: COSMOS Pharmaceutical's Attractive Valuation and Growth Potential

Mitsuru Takayanagi

Citi

¥11,200→¥11,000

Buy

43.92%

Upside

Reiterated

09/18/25

Citi Sticks to Its Buy Rating for COSMOS Pharmaceutical Corporation (3349)

Hisahiro Yamaoka

Nomura

¥11,100→¥11,500

Buy

50.46%

Upside

Reiterated

07/31/25

Nomura Reaffirms Their Buy Rating on COSMOS Pharmaceutical Corporation (3349)

Ai Furukawa

Morgan Stanley

¥9,000→¥10,400

Buy

36.07%

Upside

Reiterated

06/19/25

Morgan Stanley Sticks to Their Buy Rating for COSMOS Pharmaceutical Corporation (3349)

Dairo Murata

J.P. Morgan

¥7,500→¥9,000

Hold

17.75%

Upside

Reiterated

05/30/25

J.P. Morgan Sticks to Its Hold Rating for COSMOS Pharmaceutical Corporation (3349)

Natsuko Douglas

Macquarie

¥8,000

Sell

4.67%

Upside

Downgraded

05/12/25

Macquarie Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to UnderperformMacquarie analyst Natsuko Douglas downgraded Cosmos Pharmaceuticals Corp. (3349:JP) (OTC: CSMYF) from Neutral to Underperform with a price target of JPY8,000.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sho Kawano

Goldman Sachs

¥9,000→¥9,500

Buy

24.30%

Upside

Upgraded

12/14/25

Upgraded to Buy: COSMOS Pharmaceutical's Attractive Valuation and Growth Potential

Mitsuru Takayanagi

Citi

¥11,200→¥11,000

Buy

43.92%

Upside

Reiterated

09/18/25

Citi Sticks to Its Buy Rating for COSMOS Pharmaceutical Corporation (3349)

Hisahiro Yamaoka

Nomura

¥11,100→¥11,500

Buy

50.46%

Upside

Reiterated

07/31/25

Nomura Reaffirms Their Buy Rating on COSMOS Pharmaceutical Corporation (3349)

Ai Furukawa

Morgan Stanley

¥9,000→¥10,400

Buy

36.07%

Upside

Reiterated

06/19/25

Morgan Stanley Sticks to Their Buy Rating for COSMOS Pharmaceutical Corporation (3349)

Dairo Murata

J.P. Morgan

¥7,500→¥9,000

Hold

17.75%

Upside

Reiterated

05/30/25

J.P. Morgan Sticks to Its Hold Rating for COSMOS Pharmaceutical Corporation (3349)

Natsuko Douglas

Macquarie

¥8,000

Sell

4.67%

Upside

Downgraded

05/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COSMOS Pharmaceutical Corporation

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+1.67%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.67% per trade.

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

-1.45%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of -1.45% per trade.

1 Year

Natsuko DouglasMacquarie

Success Rate

2/2 ratings generated profit

Average Return

+18.85%

downgraded a sell rating 7 months ago

Copying Natsuko Douglas's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.85% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+18.85%

downgraded a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +18.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3349 Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 3349 has received 1 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 3349 average Analyst price target in the past 3 months is 10,250.00.

Each month's total comprises the sum of three months' worth of ratings.

3349 Financial Forecast

3349 Earnings Forecast

Next quarter’s earnings estimate for 3349 is ¥84.01 with a range of ¥81.84 to ¥86.18. The previous quarter’s EPS was ¥103.10. 3349 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 3349 has Performed in-line its overall industry.

3349 Sales Forecast

Next quarter’s sales forecast for 3349 is ¥258.29B with a range of ¥255.38B to ¥260.61B. The previous quarter’s sales results were ¥272.39B. 3349 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 3349 has Performed in-line its overall industry.

3349 Stock Forecast FAQ

What is JP:3349’s average 12-month price target, according to analysts?

Based on analyst ratings, COSMOS Pharmaceutical Corporation’s 12-month average price target is 10,250.00.

What is JP:3349’s upside potential, based on the analysts’ average price target?

COSMOS Pharmaceutical Corporation has 34.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is COSMOS Pharmaceutical Corporation a Buy, Sell or Hold?

COSMOS Pharmaceutical Corporation has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is COSMOS Pharmaceutical Corporation’s share price target?

The average share price target for COSMOS Pharmaceutical Corporation is 10,250.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥11,000.00 ,and the lowest forecast is ¥9,500.00. The average share price target represents 34.11% Increase from the current price of ¥7,643.

What do analysts say about COSMOS Pharmaceutical Corporation?

COSMOS Pharmaceutical Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of COSMOS Pharmaceutical Corporation?

To buy shares of JP:3349, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

COSMOS Pharmaceutical Corporation (3349) Stock Forecast & Price Target

3349 Analyst Ratings

3349 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering COSMOS Pharmaceutical Corporation

3349 Analyst Recommendation Trends

3349 Financial Forecast

3349 Earnings Forecast

3349 Sales Forecast

3349 Stock Forecast FAQ

Detailed List of Analyst Forecasts